Merck Clinical Trials Logo Merck Clinical Trials

Clinical Trials

Merck Clinical Trials
  • About clinical trials
    • About Clinical Trials
    • How does participation work?
    • What to consider
    • Frequently asked questions
  • Resources
    • Resources
    • For patients
    • For caregivers
  • Our medical science
  • For HCPs
  • English
    • Back
    • English
    • Español
Keynote Oncology Clinical Trials

Study Keyword: Programmed Death-Ligand 1

The purpose of this study is to compare pembrolizumab (MK-3475) in combination with sacituzumab govitecan with pembrolizumab alone with respect to progression-free survival (PFS) and overall survival (OS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR) among adults with metastatic non-small cell lung cancer (NSCLC) with programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%).

Study of Pembrolizumab Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer With Programmed Cell Death Ligand 1 Tumor Proportion Score ≥50%

January 27, 2023

By Harrison

The purpose of this study is to compare pembrolizumab (MK-3475) in combination with sacituzumab govitecan with pembrolizumab alone with respect to progression-free survival (PFS) and overall survival (OS) per Response Evaluation

Evaluation of Co-formulated Pembrolizumab/Quavonlimab Versus Other Treatments in Participants With Microsatellite Instability-High or Mismatch Repair Deficient Stage IV Colorectal Cancer

October 9, 2022

By clique_admin

The purpose of this study is to assess the efficacy and safety of co-formulated pembrolizumab/quavonlimab versus other treatments in participants with MSI-H or dMMR Metastatic Stage IV Colorectal Cancer.

Efficacy and Safety Study of Stereotactic Body Radiotherapy With or Without Pembrolizumab in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer

October 9, 2022

By clique_admin

The purpose of this study is to assess the efficacy and safety of stereotactic body radiotherapy (SBRT) plus pembrolizumab (MK-3475) in the treatment of adult participants with unresected stage I or

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer

October 9, 2022

By clique_admin

The purpose of this study is to compare overall survival (OS) and progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by blinded

A Study of Pembrolizumab in Combination With Belzutifan and Lenvatinib, or Pembrolizumab/Quavonlimab in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma

October 9, 2022

By clique_admin

The goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in participants

Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer

October 9, 2022

By clique_admin

The primary objective is to compare pembrolizumab plus paclitaxel with or without bevacizumab to placebo plus paclitaxel with or without bevacizumab, with respect to progression-free survival (PFS) per Response Evaluation Criteria

MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors

October 9, 2022

By clique_admin

The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer therapies in participants with selected advanced solid tumors.

Study of Pembrolizumab Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy

October 9, 2022

By clique_admin

The purpose of this study is to assess the efficacy and safety of treatment with definitive chemoradiotherapy (dCRT) + pembrolizumab (MK-3475) compared to treatment with dCRT + placebo with respect to

Safety and Efficacy of Pembrolizumab in Children and Young Adults With Classical Hodgkin Lymphoma

October 9, 2022

By clique_admin

This study will examine the safety and efficacy of pembrolizumab (MK-3475) in combination with chemotherapy in children and young adults with newly diagnosed classical Hodgkin Lymphoma (cHL) who are slow early

Study of Pembrolizumab in Participants With Advanced Solid Tumors

October 9, 2022

By clique_admin

In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors who have progressed on standard of care therapy will be treated with pembrolizumab (MK-3475).

Posts navigation

Older posts
Merck Clinical Trials Logo Merck Clinical Trials
  • Merck.com
  • Privacy Policy
  • Terms of Use
  • Policies & Perspectives
  • Cookie Preferences
  • Accessibility

Copyright © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.

THIS WEBSITE IS INTENDED FOR A UNITED STATES AUDIENCE ONLY

Merck Essential Accessibility

Merck Essential Accessibility